Immuron Limited

What they do

Immuron develops and commercializes targeted polyclonal antibodies delivered within the gastrointestinal tract that do not cross into the bloodstream. Its commercial products are Travelan, an over-the-counter medicine indicated to reduce the risk of travelers' diarrhea, and Protectyn, an immune supplement for digestive and liver function. Travelan is sold in Australian pharmacies, is licensed in Canada as a natural health product, and is sold in the U.S. as a dietary supplement. The company is also developing drug candidates for Enterotoxigenic Escherichia coli (ETEC) infections and Clostridioides difficile (C. difficile) infections.

Revenue drivers

• Travelan (Australia) — Flagship commercial product, an over-the-counter listed medicine (AUST L 106709) sold in pharmacies throughout Australia to reduce the risk of travelers' diarrhea.
• Protectyn (Australia) — Listed medicine (AUST L 231001) sold online and in health practitioner clinics, marketed as an immune supplement to help maintain healthy digestive function and liver.
• Travelan (Canada) — Licensed as a natural health product (NPN 80046016) indicated to reduce the risk of travelers' diarrhea.
• Travelan (U.S.) — Marketed as a dietary supplement for digestive tract protection.

Recent performance

The filing does not disclose revenue, net income, or sales figures for the fiscal year ended June 30, 2025. The company describes itself as commercial and clinical-stage, with existing commercial products Travelan and Protectyn generating sales in Australia, Canada, and the U.S. No actual financial results are provided in this excerpt.

Strategy

Immuron seeks to increase sales of its existing commercial products and expand its product portfolio and distribution capability. The company is advancing its lead drug candidates into clinical development, targeting ETEC infections, travelers' diarrhea, and C. difficile infections. Its polyclonal antibody platform is designed for GI-tract delivery without crossing into the bloodstream, aiming for improved safety and tolerability. Management believes these candidates have the potential to transform existing treatment paradigms. The company also maintains listings on NASDAQ (IMRN) and the Australian Securities Exchange (IMC).

Risks

• Clinical development risk — Lead drug candidates for ETEC and C. difficile infections are in early clinical development and may fail to demonstrate safety or efficacy.
• Commercial concentration — Revenue depends heavily on Travelan and Protectyn sales, primarily in Australia, Canada, and the U.S.
• Regulatory risk — Products are regulated differently across jurisdictions, such as listed medicines in Australia, a natural health product in Canada, and a dietary supplement in the U.S., creating compliance complexity.
• Foreign private issuer and currency risk — As an Australian company reporting in Australian dollars with ADSs on NASDAQ, Immuron is exposed to currency fluctuations and U.S. securities regulations for foreign private issuers.

Outlook

The filing does not include specific financial guidance. Management states it seeks to increase sales of existing commercial products and expand its product portfolio and distribution capability. The company is prioritizing clinical development of its polyclonal antibody candidates for ETEC and C. difficile infections. No timeline or spending commitments are provided in this excerpt.